Is Wall Avenue Bullish or Bearish?

Amgen Inc. (AMGN) is a number one biotechnology firm headquartered in Thousand Oaks, California. It specializes within the discovery, improvement, manufacturing, and supply of modern human therapeutics, significantly biologics that focus on severe diseases comparable to most cancers, heart problems, irritation, and bone issues. Amgen pioneered recombinant DNA know-how to advance affected person care globally. The corporate has a market capitalization of $184.10 billion.

The inventory has been dealing with strong investor sentiment. Over the previous 52 weeks, Amgen’s inventory has gained 20.4%, whereas over the previous six months, it has risen 13.4%. The corporate’s shares reached a 52-week excessive of $353.25 on Jan. 27, however are down 3.2% from that stage.

Alternatively, the broader S&P 500 Index ($SPX) has gained 14.3% and 9.1% over the identical durations, respectively, indicating that the inventory has outperformed the broader market. Subsequent, we evaluate the inventory with its personal sector. The State Avenue Well being Care Choose Sector SPDR ETF (XLV) has elevated 5% over the previous 52 weeks and 15.3% over the previous six months. Due to this fact, whereas the inventory has outperformed its sector over the previous yr, it has underperformed over the previous six months.

Amgen is taking some strategic strides to bolster its enterprise. Fitch Rankings acknowledged the corporate’s improved monetary construction and debt reimbursement after the acquisition of Horizon Therapeutics by elevating its long-term issuer default score from “BBB” to “BBB+.” The corporate additionally acquired a U.Ok.-based biotech agency, Darkish Blue Therapeutics, which is anticipated to bolster Amgen’s oncology portfolio.

The corporate’s third-quarter outcomes have been higher than what analysts had anticipated. For the fourth quarter of 2025 (to be reported on Feb. 3, after the market closes), Wall Avenue analysts count on Amgen’s EPS to say no 10.6% YOY to $4.75 on a diluted foundation. Nevertheless, EPS is anticipated to extend 7.3% yearly to $21.29 for fiscal 2025, adopted by a 2.6% enchancment to $21.85 in fiscal 2026. The corporate has a strong historical past of surpassing consensus estimates, topping them in all 4 trailing quarters.

Among the many 33 Wall Avenue analysts overlaying Amgen’s inventory, the consensus is a “Reasonable Purchase.” That’s based mostly on 14 “Sturdy Purchase” rankings, two “Reasonable Buys,” 14 “Holds,” one “Reasonable Promote,” and two “Sturdy Sells.” The rankings configuration has grow to be extra bullish than two months in the past, with 14 “Sturdy Purchase” rankings, up from 13.

Not too long ago, analysts at Bernstein downgraded Amgen’s inventory from “Outperform” to “Market Carry out,” citing that 2026 might be a “ready yr” for the inventory, as its weight problems candidate MariTide awaits its first Section 3 trial information and its ldl cholesterol drug Repatha faces competitors from Merck’s (MRK) oral PCSK9 inhibitor, Enlicitide.

Amgen’s imply value goal of $336.29 signifies a 1.6% draw back over present market costs. Nevertheless, the Avenue-high value goal of $425 implies a possible upside of 24.3%.

On the date of publication, Anushka Dutta didn’t have (both straight or not directly) positions in any of the securities talked about on this article. All info and information on this article is solely for informational functions. This text was initially revealed on Barchart.com